Publication

Cost-effectiveness of laparoscopy as diagnostic tool before primary cytoreductive surgery in ovarian cancer

van de Vrie, R., van Meurs, H. S., Rutten, M. J., Naaktgeboren, C. A., Opmeer, B. C., Gaarenstroom, K. N., van Gorp, T., Ter Brugge, H. G., Hofhuis, W., Schreuder, H. W. R., Arts, H. J. G., Zusterzeel, P. L. M., Pijnenborg, J. M. A., van Haaften, M., Engelen, M. J. A., Boss, E. A., Vos, M. C., Gerestein, K. G., Schutter, E. M. J., Kenter, G. G., Bossuyt, P. M. M., Mol, B. W. & Buist, M. R., Sep-2017, In : Gynecologic Oncology. 146, 3, p. 449-456 8 p.

Research output: Contribution to journalArticleAcademicpeer-review

Copy link to clipboard

Documents

  • Cost-effectiveness of laparoscopy as diagnostic tool before primary cytoreductive surgery in ovarian cancer

    Final publisher's version, 851 KB, PDF document

DOI

  • Roelien van de Vrie
  • Hannah S. van Meurs
  • Marianne J. Rutten
  • Christiana A. Naaktgeboren
  • Brent C. Opmeer
  • Katja N. Gaarenstroom
  • Toon van Gorp
  • Henk G. Ter Brugge
  • Ward Hofhuis
  • Henk W. R. Schreuder
  • Henriette J. G. Arts
  • Petra L. M. Zusterzeel
  • Johanna M. A. Pijnenborg
  • Maarten van Haaften
  • Mirjam J. A. Engelen
  • Erik A. Boss
  • M. Caroline Vos
  • Kees G. Gerestein
  • Eltjo M. J. Schutter
  • Gemma G. Kenter
  • Patrick M. M. Bossuyt
  • Ben Willem Mol
  • Marrije R. Buist

Objective. To evaluate the cost-effectiveness of a diagnostic laparoscopy prior to primary cytoreductive surgery to prevent futile primary cytoreductive surgery (i.e. leaving >1 cm residual disease) in patients suspected of advanced stage ovarian 'cancer.

Methods. An economic analysis was conducted alongside a randomized controlled trial in which patients suspected of advanced stage ovarian cancer who qualified for primary cytoreductive surgery were randomized to either laparoscopy or primary cytoreductive surgery. Direct medical costs from a health care perspective over a 6-month time horizon were analyzed. Health outcomes were expressed in quality-adjusted life-years (QALYs) and utility was based on patient's response to the EQ-5D questionnaires. We primarily focused on direct medical costs based on Dutch standard prices.

Results. We studied 201 patients, of whom 102 were randomized to laparoscopy and 99 to primary cytoreductive surgery. No significant difference in QALYs (utility = 0.01; 95% CI 0.006 to 0.02) was observed. Laparoscopy reduced the number of futile laparotomies from 39% to 10%, while its costs were (sic) 1400 per intervention, making the overall costs of both strategies comparable (difference (sic) - 80 per patient (95% CI - 470 to 300)). Findings were consistent across various sensitivity analyses.

Conclusion. In patients with suspected advanced stage ovarian cancer, a diagnostic laparoscopy reduced the number of futile laparotomies, without increasing total direct medical health care costs, or adversely affecting complications or quality of life.

Original languageEnglish
Pages (from-to)449-456
Number of pages8
JournalGynecologic Oncology
Volume146
Issue number3
Publication statusPublished - Sep-2017

    Keywords

  • Cost-effectiveness, Ovarian cancer, Diagnostic laparoscopy, Cytoreductive surgery, Quality of life, PRIMARY DEBULKING SURGERY, QUALITY-OF-LIFE, NEOADJUVANT CHEMOTHERAPY, PHASE-III, TRIALS, ONCOLOGY, PREDICTION

ID: 49359614